Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Dec 19;12(12):CD012346.
doi: 10.1002/14651858.CD012346.pub2.

Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease

Justyna Pollok  1 , Joep Em van Agteren, Kristin V Carson-Chahhoud
Affiliations

Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease

Justyna Pollok et al. Cochrane Database Syst Rev. .

Abstract

Background: Studies report that up to 80% of individuals with chronic obstructive pulmonary disease (COPD) may struggle with symptoms of depression. However, this major comorbidity in COPD is rarely managed effectively. A number of recent studies indicate that left untreated, COPD-related depression is associated with worse quality of life, worse compliance with COPD treatment plan, increased exacerbations, hospital admissions, and healthcare costs when compared to individuals with COPD without depression. Regrettably, COPD practice guidelines do not provide conclusive treatment recommendations for the use of antidepressants in patients with COPD, and base their guidelines on findings from trials in the general population. This may be problematic, as there is an elevated risk of respiratory issues associated with antidepressant treatment and COPD. Evaluating effectiveness and safety of pharmacological interventions specifically for patients with COPD and depression was therefore paramount.

Objectives: To assess the effectiveness and safety of pharmacological interventions for the treatment of depression in patients with COPD.

Search methods: The last search was performed on 26 November 2018. We initially searched the following databases via the Specialised Trials Registers of the Cochrane Airways and Common Mental Disorders Groups (to June 2016): MEDLINE, Embase, PsycINFO, CINAHL, AMED, and the Cochrane Library trials register (CENTRAL). Searches from June 2016 to November 2018 were performed directly on Ovid MEDLINE, Embase, PsycINFO and the Cochrane Library (Issue 11, 2018). We searched ClinicalTrials.gov, the ISRCTN registry, and the World Health Organization International Clinical Trials Registry Platform to 26 November 2018. We searched the grey literature databases to identify studies not indexed in major databases and the reference lists of studies initially identified for full-text screening.

Selection criteria: All published and unpublished randomised controlled trials (RCTs) comparing the efficacy of pharmacological interventions with no intervention, placebo or co-intervention in adults with diagnosed COPD and depression were eligible for inclusion.

Data collection and analysis: Two review authors independently assessed articles identified by the search for eligibility. Our primary outcomes were change in depressive symptoms and adverse events. The secondary outcomes were: change in quality of life, change in dyspnoea, change in forced expiratory volume in one second (FEV1), change in exercise tolerance, change in hospital utilisation (length of stay and readmission rates), and cost-effectiveness. For continuous outcomes, we calculated the pooled mean difference (MD) or standardised mean difference (SMD) with 95% confidence interval (CI) as appropriate. For dichotomous outcomes, we calculated the pooled odds ratio (OR) and corresponding 95% CI using a random-effects model. We assessed the quality of evidence using the GRADE framework.

Main results: Of the 1125 records screened for eligibility, four RCTs (N = 201 participants), and one on-going study, met the inclusion criteria. Two classes of antidepressants were investigated in two separate comparisons with placebo: a tricyclic antidepressant (TCA) and selective serotonin reuptake inhibitors (SSRIs).TCA versus placeboOnly one RCT (N = 30 participants) provided results for this comparison.Primary outcomesThe TCA (nortriptyline) reduced depressive symptoms post-treatment compared to placebo (MD -10.20, 95% CI -16.75 to -3.65; P = 0.007; very low-quality evidence), as measured by the Hamilton Depression Rating Scale (HAM-D). Three participants withdrew from the trial due to adverse events related to the tested antidepressant (dry mouth, sedation, orthostatic hypotension).Secondary outcomesThe overall results post-treatment indicated that nortriptyline was not effective in improving the quality of life of individuals with COPD, as measured by the Sickness Impact Profile (MD -2.80, 95% CI -11.02 to 5.42; P = 0.50; very low-quality evidence).The results for the change in dyspnoea for the domains examined (e.g. dyspnoea scores for 'most day-to-day activities') post-treatment showed no improvement in the intervention group (MD 9.80, 95% CI -6.20 to 25.80; P = 0.23; very low-quality evidence).No data were reported for change in FEV1, change in exercise tolerance, change in hospital utilisation, or cost-effectiveness. The TCA study provided short-term results, with the last follow-up data collection at 12 weeks.The quality of the evidence for all the outcomes evaluated was very low due to a small sample size, imprecision, attrition, and selection and reporting bias.SSRIs versus placeboThree RCTs (N = 171 participants) provided results for this comparison.Primary outcomesThe pooled results for two studies showed no difference for the change in depressive symptoms post-intervention (SMD 0.75, 95% CI -1.14 to 2.64; 148 participants; 2 studies; P = 0.44; very low-quality evidence). High heterogeneity was observed (I² = 95%), limiting the reliability of these findings.While it was not possible to meta-analyse the total adverse events rates across the studies, it was possible to combine the results for two medication-specific adverse effects: nausea and dizziness. There were no significant post-treatment group differences for nausea (OR 2.32, 95% CI 0.66 to 8.12; 171 participants; 3 studies; P = 0.19; very low-quality evidence) or dizziness (OR 0.61, 95% CI 0.09 to 4.06; 143 participants; 2 studies; P = 0.61; very low-quality evidence).Secondary outcomesThe pooled analysis of two trials reporting data for the change in quality of life did not show improvement post-treatment in the intervention group compared to placebo (SMD 1.17, 95% CI -0.80 to 3.15; 148 participants; 2 studies; P = 0.25; very low-quality evidence).There was no difference between groups in change in FEV1 post-treatment (MD 0.01, 95% CI -0.03 to 0.05; 148 participants; 2 studies; P = 0.60; low-quality evidence). However, two trials reported improvement in exercise tolerance in the SSRI group versus the placebo group (MD 13.88, 95% CI 11.73 to 16.03; 148 participants; 2 studies; P < 0.001; very low-quality evidence).The trials included in this comparison did not report data related to the change in dyspnoea, hospital utilisation rates, or cost-effectiveness.

Authors' conclusions: There is insufficient evidence to make definitive statements about the efficacy or safety of antidepressants for treating COPD-related depression. New RCTs are needed; with better methodological quality and more accurate reporting of the methods used. Moreover, longer-term follow-up data collection is needed, including outcomes such as adverse events, hospital utilisation and cost-effectiveness.

PubMed Disclaimer

Conflict of interest statement

Justyna Pollok: none known Joep van Agteren: none known Kristin Carson‐Chahhoud: none known

Figures

1
1
Study Flow Diagram.
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
4
4
Forest plot of comparison: 1 Tricylic antidepressant versus placebo, outcome: 1.4 Change in dyspnoea (Pulmonary Functional Status Instrument).
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD012346

References

References to studies included in this review

Borson 1992 {published data only}
    1. Borson S, McDonald GJ, Gayle T, Deffebach M, Lakshminarayan S, VanTuinen C. Improvement in mood, physical symptoms, and function with nortriptyline for depression in patients with chronic obstructive pulmonary disease. Psychosomatics 1992;33(2):190‐201. [DOI: 10.1016/S0033-3182(92)71995-1] - DOI - PubMed
Eiser 2005 {published data only}
    1. Eiser N, Harte R, Karvounis S, Phillips C, Isaac MT. Effect of treating depression on quality‐of‐life and exercise tolerance in severe COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease 2005;2(2):233‐41. [DOI: 10.1081/COPD-57596] - DOI - PubMed
He 2016 {published data only}
    1. He Y, Zheng Y, Xu C, Yang H, Wang Z, Zhou L, et al. Sertraline hydrochloride treatment for patients with stable chronic obstructive pulmonary disease complicated with depression: a randomized controlled trial. The Clinical Respiratory Journal 2016;10(3):318‐25. [DOI: 10.1111/crj.12219] - DOI - PubMed
Lacasse 2004 {published data only}
    1. Lacasse Y, Beaudoin L, Rousseau L, Maltais F. Randomized trial of paroxetine in end‐stage COPD. Monaldi Archives for Chest Disease 2004;61(3):140‐7. [DOI: 10.4081/monaldi.2004.692] - DOI - PubMed

References to studies excluded from this review

Gordon 1985 {published data only}
    1. Gordon GH, Michiels TM, Mahutte CK, Light RW. Effect of desipramine on control of ventilation and depression scores in patients with severe chronic obstructive pulmonary disease. Psychiatry Research 1985;15(1):25‐32. - PubMed
Light 1986 {published data only}
    1. Light RW, Merrill EJ, Despars J, Gordon GH, Mutalipassi LR. Doxepin treatment of depressed patients with chronic obstructive pulmonary disease. Archives of Internal Medicine 1986;146(7):1377‐80. [DOI: 10.1001/archinte.1986.00360190155022] - DOI - PubMed
Moisieva 2018 {published data only}
    1. Moisieieva NV, Burya LV, Kapustianskaya AA, Kolenko IA, Rumyantseva MA, Shumeiko OH. Comprehensive patterns of comorbidity: COPD and depression. Aspects of treatment. Wiadomosci Lekarskie 2018;71(3):588‐91. - PubMed
Momtaz 2015 {published data only}
    1. Momtaz OM, Rabei SM, Tawfike NR, Hasan AA. Effect of treatment of depression and anxiety on physiological state of severe COPD patients. Egyptian Journal of Chest Disease and Tuberculosis 2015;64:29‐34.
Singh 1993 {published data only}
    1. Singh NP, Despars JA, Stansbury DW, Avalos K, Light RW. Effects of buspirone on anxiety levels and exercise tolerance in patients with chronic airflow obstruction and mild anxiety. Chest 1993;103(3):800. - PubMed
Strom 1995 {published data only}
    1. Strom K, Boman G, Pehrsson K, Alton M, Singer J, Rydstrom P‐O, et al. Effect of protriptyline, 10 mg daily, on chronic hypoxaemia in chronic obstructive pulmonary disease. European Respiratory Journal 1995;8(3):425‐9. - PubMed
Subbe 2004 {published and unpublished data}
    1. Subbe C, Collier G, Bedson E, Meknkes D. Effect of citalopram on health status, anxiety and depression in patients with chronic obstructive pulmonary disease: a pilot study. trial protocol.
    1. Subbe C, Collier G, Bedson E, Menkes D. Pilot study to examine the effect of citalopram on health status, anxiety and depression in patients with chronic obstructive pulmonary disease. unpublished data.
Yohannes 2001 {published data only}
    1. Yohannes AM, Connolly MJ, Baldwin RC. A feasibility study of antidepressant drug therapy in depressed elderly patients with chronic obstructive pulmonary disease. International Journal of Geriatric Psychiatry 2001;16(5):451‐4. [DOI: 10.1002/gps.461] - DOI - PubMed

References to ongoing studies

Mathews 2016 {published data only}
    1. Mathews AM, Kuehn H. Safety of anti‐depressant for Chronic Obstructive Pulmonary Disease (SAD‐COPD). ClinicalTrials.gov NCT02813447 (first received 27 June 2016).

Additional references

Abrams 2011
    1. Abrams TE, Vaughan‐Sarrazin M, Weg MW. Acute exacerbations of chronic obstructive pulmonary disease and the effect of existing psychiatric comorbidity on subsequent mortality. Psychosomatics 2011;52(5):441–9. - PubMed
Allen 2009
    1. Allen NJ, Barres BA. Neuroscience: glia ‐ more than just brain glue. Nature 2009;457(7230):675‐7. - PubMed
Almagro 2002
    1. Almagro P, Calbo E, Ochoa de Echaguen A, Barreiro B, Quintana S, Heredia JL, et al. Mortality after hospitalization for COPD. Chest 2002;121(5):1441–8. - PubMed
Anderson 2000
    1. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta‐analysis of efficacy and tolerability. Journal of Affective Disorders 2000;58(1):19‐36. - PubMed
APA 2000
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington, DC: American Psychiatric Association, 2000.
APA 2013
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th Edition. Washington, DC: American Psychiatric Publishing, 2013.
Arroll 2009
    1. Arroll B, Elley CR, Fishman T, Goodyear‐Smith FA, Kenealy T, Blashki G, et al. Antidepressants versus placebo for depression in primary care: review. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007954] - DOI - PMC - PubMed
Atlantis 2013
    1. Atlantis E, Fahey P, Cochrane B, Smith S. Biodirectional associations between clinically relevant depression or anxiety and COPD: a systematic review and meta‐analysis. Chest 2013;144(3):766‐77. - PubMed
ATS 2002
    1. American Thoracic Society. ATS statement: guidelines for the six‐minute walk test. American Journal of Respiratory and Critical Care Medicine 2002;166:111‐7. - PubMed
Beck 1961
    1. Beck AT, Ward CH. An inventory for measuring depression. Archives of General Psychiatry 1961;4:561‐71. - PubMed
Bentsen 2013
    1. Bentsen SB, Miaskowski C, Rustoen T. Demographic and clinical characteristics associated with quality of life in patients with chronic obstructive pulmonary disease. Quality of Life Research 2014;23:991‐8. - PubMed
Bespalov 2007
    1. Bespalov MM, Saarma M. GDNF family receptor complexes are emerging drug targets. Trends in pharmacological sciences 2007;28(2):68‐74. - PubMed
BLF 2006
    1. British Lung Foundation. Lost in Translation: Bridging the Communication Gap in COPD: a Report by the British Lung Foundation. London: British Lung Foundation, 2006.
Borg 1982
    1. Borg GAV. Psychophysical basis of perceived exertion. Medicine and Science in Sports and Exercise 1982;14(5):377‐81. - PubMed
Butland 1982
    1. Butland RJ, Pang J, Gross ER, Woodcock AA, Geddes DM. Two‐, six‐, and 12‐minute walking tests in respiratory disease. British Medical Journal 1982;284(6329):1607‐8. - PMC - PubMed
Cafarella 2012
    1. Cafarella PA, Effing TW, Usmani ZA, Frith PA. Treatments for anxiety and depression in patients with chronic obstructive pulmonary disease: a literature review. Respirology 2012;17:627‐38. - PubMed
Campbell 2000
    1. Campbell M, Grimshaw J, Steen N. Sample size calculations for cluster randomised trials. Changing professional practice in Europe Group (EU BIOMED II Concerted Action). Journal of Health Services Research and Policy 2000;5(1):12‐16. - PubMed
Carey 2016
    1. Carey K, Stefos T. The cost of hospital readmissions: evidence from the VA. Health Care Management Science 2016;19(3):241‐8. - PubMed
Cosco 2011
    1. Cosco T, Doyle F, Ward M, McGee H. Latent structure of the Hospital Anxiety and Depression Scale: A 10‐year systematic review. Journal of Psychosomatic Research 2012;72(3):180‐4. - PubMed
Coventry 2013
    1. Coventry PA, Bower P, Keyworth C, Kenning C, Knopp J, Garrett C, et al. The effect of complex interventions on depression and anxiety in chronic obstructive pulmonary disease: systematic review and meta‐analysis. PLoS ONE 2013;8(4):e60532. - PMC - PubMed
Cully 2006
    1. Cully JA, Graham DP, Stanley MA, Ferguson CJ, Sharafkhaneh A, Souchek J, et al. Quality of life in patients with chronic obstructive pulmonary disease and comorbid anxiety or depression. Psychosomatics 2006;47(4):312‐9. - PubMed
Dalal 2011
    1. Dalal AA, Shah M, Lunacsek O, Hanania NA. Clinical and economic burden of depression/anxiety in chronic obstructive pulmonary disease patients within a managed care population. COPD: Journal of Chronic Obstructive Pulmonary Disease 2011;8:293‐9. - PubMed
de Godoy 2003
    1. Godoy DV, Godoy RF. A randomised controlled trial of the effect of psychotherapy on anxiety and depression in chronic obstructive pulmonary disease. Archives of Physical Medicine and Rehabilitation 2003;84:1154‐8. - PubMed
de Voogd 2009
    1. Voogd JN, Wempe JB, Koëter GH, Postema K, Sonderen E, Ranchor AV, et al. Depressive symptoms as predictors of mortality in patients with COPD. Chest Journal 2009;135(3):619–25. - PubMed
Deeks 2017
    1. Deeks JJ, Higgins JP, Altman DG, editor(s) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking metaanalyses. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017. Available from handbook.cochrane.org.
DeJean 2013
    1. DeJean D, Giacomini M, Vanstone M, Brundisini F. Patient experiences of depression and anxiety with chronic disease: a systematic review and qualitative meta‐synthesis. Health Quality Ontario 2013;13(16):1‐33. - PMC - PubMed
Di Marco 2006
    1. Marco F, Verga M, Reggenta M, Maria Casanova F, Santus P, Blasi F, et al. Anxiety and depression in COPD patients: the roles of gender and disease severity. Respiratory Medicine 2006;100(10):1767‐74. - PubMed
Dinicola 2013
    1. Dinicola G, Julian L, Gregorich SE, Blan PD, Katz PP. The role of social support in anxiety for persons with COPD. Journal of Psychosomatic Research 2013;74(2):110‐5. - PMC - PubMed
Egger 1997
    1. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315(7109):629‐34. - PMC - PubMed
Evans 1997
    1. Evans M, Hammond M, Wilson K, Lye M, Copeland J. Placebo‐controlled treatment trial of depression in elderly physically ill patients. International Journal of Geriatric Psychiatry 1997;12:817‐24. - PubMed
Fan 2007
    1. Fan VS, Ramsey SD, Giardino ND, Make BJ, Emery CF, Diaz PT, et al. National Emphysema Treatment Trial (NETT) Research Group. Sex, depression, and risk of hospitalization and mortality in chronic obstructive pulmonary disease. Archives of Internal Medicine 2007;167(21):2345–53. - PubMed
Felker 2010
    1. Felker B, Bush KR, Harel O, Shofer JB, Shores MM, Au DH. Added burden of mental disorders on health status among patients with chronic obstructive pulmonary disease. Primary Care Companion to the Journal of Clinical Psychiatry 2010;12(4):PCC.09m00858. [DOI: 10.4088/PCC.09m00858gry] - DOI - PMC - PubMed
Ferguson 2001
    1. Ferguson JM. SSRI antidepressant medications: adverse effects and tolerability. Primary Care Companion to the Journal of Clinical Psychiatry 2001;3(1):22. - PMC - PubMed
Fleehart 2014
    1. Fleehart S, Fan VS, Nguyen HQ, Lee J, Kohen R, Herting JR, et al. Prevalence and correlates of suicide ideation in patients with COPD: a mixed methods study. International Journal of Chronic Obstructive Pulmonary Disease 2014;10:1321‐9. - PMC - PubMed
Glassman 2002
    1. Glassman AH, O'Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002;288(6):701‐9. - PubMed
GOLD 2018 update
    1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Global Initiative for Chronic Obstructive Lung Disease; Revised 2018. www.goldcopd.org/wp‐content/uploads/2017/11/GOLD‐2018‐v6.0‐FINAL‐revised... 2018 (accessed prior to 2 November 2018):1‐142.
Goodwin 2012
    1. Goodwin RD, Lavoie KL, Lemeshow AR, Jenkins E, Brown ES, Fedoronko DA. Depression, anxiety and COPD: the unexamined role of nicotine dependence. Nicotine and Tobacco Research 2012;14(2):176‐83. - PMC - PubMed
GRADEpro GDT 2015 [Computer program]
    1. GRADE Working Group. GRADEpro GDT. Version accessed prior to 2 November 2018. Hamilton ON: McMaster University (developed by Evidence Prime), 2015.
Groenewegen 2003
    1. Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality‐related factors after hospitalization for acute exacerbation of COPD. Chest 2003;124(2):459–67. - PubMed
Gudmundsson 2005
    1. Gudmundsson G, Gislason T, Janson C, Lindberg E, Hallin R, Ulrik CS, et al. Risk factors for rehospitalisation in COPD: role of health status, anxiety and depression. European Respiratory Journal 2005;26(3):414‐9. - PubMed
Hamilton 1960
    1. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 1960;23:56‐62. - PMC - PubMed
Hanania 2011
    1. Hanania NA, Müllerova H, Locantore NW, Vestbo J, Watkins ML, Wouters EF, et al. the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study investigators. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. American Journal of Respiratory and Critical Care Medicine 2011;183:604–11. - PubMed
Hickie 2011
    1. Hickie IB. Antidepressants in elderly people. BMJ 2011;343:d4660. - PubMed
Higgins 2011
    1. Higgins JP, Deeks JJ, Altman DG, on behalf of the Cochrane Statistical Methods Group Green S (editors). Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins 2017
    1. Higgins JPT, Altman DG, Sterne JAC, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017.. Available from handbook.cochrane.org.
Hisaoka‐Nakashima 2015
    1. Hisaoka‐Nakashima K, Miyano K, Matsumoto C, Kajitani N, Abe H, Okada‐Tsuchioka M, et al. Tricyclic antidepressant amitriptyline‐induced glial cell line‐derived neurotrophic factor production involves pertussis toxin‐sensitive gαi/o activation in astroglial cells. Journal of Biological Chemistry 2015;290(22):13678‐91. - PMC - PubMed
Howard 2014
    1. Howard C, Dupont S. 'The COPD breathlessness manual': a randomised controlled trial to test a cognitive‐behavioural manual versus information booklets on health service use, mood and health status, in patients with chronic obstructive pulmonary disease. Primary Care Respiratory Medicine 2014;24:14076. - PMC - PubMed
Hutter 2010
    1. Hutter N, Schnurr A, Baumeister H. Health care costs in patients with diabetes mellitus and comorbid mental disorders ‐ a systematic review. Diabetologia 2010;53(12):2470‐9. - PubMed
Hynninen 2010
    1. Hynninen MJ, Bjerke N, Pallesen S, Bakke PS, Nordhus IH. A randomised controlled trial of cognitive behavioral therapy for anxiety and depression in COPD. Respiratory Medicine 2010;104:986‐94. - PubMed
Jones 1991
    1. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respiratory Medicine 1991;85(Suppl B):25‐31. - PubMed
Karajgi 1990
    1. Karajgi B, Rifkin A, Doddi S, Kolli R. The prevalence of anxiety disorders in patients with chronic obstructive pulmonary disease. American Journal of Psychiatry 1990;147:200‐1. - PubMed
Kessler 2005
    1. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12‐month DSM‐IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry 2005;62(6):617–27. - PMC - PubMed
Kim 2000
    1. Kim HF, Kunik ME, Molinari VA, Hillman SL, Lalani S, Orengo CA, et al. Functional impairment in COPD patients: the impact of anxiety and depression. Psychosomatics 2000;41(6):465‐71. - PubMed
Kim 2014
    1. Kim KU, Park HK, Jung HY, Ahn JJ, Moon E, Kim YS, et al. Association of depression with disease severity in patients with chronic obstructive pulmonary disease. Lung 2014;192:243‐9. - PubMed
Kunik 2005
    1. Kunik ME, Roundy K, Veazey C, Souchek J, Richardson P, Wray NP, et al. Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. Chest 2005;127(4):1205‐11. - PubMed
Kunik 2008
    1. Kunik ME, Veazey C, Cully JA, Souchek J, Graham DP, Hopko D, et al. COPD education and cognitive behavioral therapy group treatment for clinically significant symptoms of depression and anxiety in COPD patients: a randomised controlled trial. Psychological Medicine 2008;38:385‐96. - PubMed
Lamers 2010
    1. Lamers F, Jonkers CCM, Bosma H, Chavannes NH, Knottnerus JA, Eijk JT. Improving quality of life in depressed COPD patients: effectiveness of a minimal psychological intervention. COPD: Journal of Chronic Obstructive Pulmonary Disease 2010;7(5):315‐22. - PubMed
Lamprecht 2011
    1. Lamprecht B, McBurnie MA, Vollmer WM, Gudmundsson G, Welte T, Nizankowska‐Mogilnicka E, et al. COPD in never smokers. Results from the population‐based burden of obstructive lung disease study. Chest 2011;139(4):752‐63. - PMC - PubMed
Lecheler 2017
    1. Lecheler L, Richter M, Franzen DP, Rampini SK, Cheetham M, Jenewein J, et al. The frequent and underrecognised co‐occurrence of acute exacerbated COPD and depression warrants screening: a systematic review. European Respiratory Review 2017;26:144. - PMC - PubMed
Lee 2015
    1. Lee H, Yoon JY, Lim Y, Jung H, Kim S, Yoo Y, et al. The effect of nurse‐led problem‐solving therapy on coping, self‐efficacy and depressive symptoms for patients with chronic obstructive pulmonary disease: a randomised controlled trial. Age and Ageing 2015;44(3):397‐403. - PubMed
Lopez 2006
    1. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, et al. Chronic obstructive pulmonary disease: current burden and future projections. European Respiratory Journal 2006;27(2):397‐412. - PubMed
Lovibond 1995
    1. Lovibond SH, Lovibond PF. Manual for Depression Anxiety Stress Scales. 2nd Edition. Sydney: The Psychology Foundation, University of New South Wales, 1995.
Marciniuk 2011
    1. Marciniuk DD, Goodridge D, Hernandez P, Rocker G, Balter M, Bailey P, et al. Managing dyspnea in patients with advanced chronic obstructive pulmonary disease: a Canadian Thoracic Society clinical practice guideline. Canadian Respiratory Journal 2011;18(2):69‐78. - PMC - PubMed
Masson 2013
    1. Masson SC, Tejani AM. Minimum clinically important differences identified for commonly used depression rating scales. Journal of Clinical Epidemiology 2013;66(7):805‐7. - PubMed
Mathers 2006
    1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Medicine 2006;3(11):e442. - PMC - PubMed
Maurer 2008
    1. Maurer J, Rebbapragada V, Borson S, Goldstein R, Kunik ME, Yohannes AM, et al. Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest 2008;134:43S‐53S. - PMC - PubMed
McHugh 2013
    1. McHugh RK, Whitton SW, Peckham AD, Welge JA, Otto MW. Patient preference for psychological vs pharmacologic treatment of psychiatric disorders: a meta‐analytic review. Journal of Clinical Psychiatry 2013;74(6):595‐602. - PMC - PubMed
Meader 2011
    1. Meader N, Mitchell A, Chew‐Graham C, Goldberg D, Rizzo M, Bird V, et al. Case identification of depression in patients with chronic physical health problems: a diagnostic accuracy meta‐analysis of 113 studies. British Journal of General Practice 2011;61(593):e808‐20. - PMC - PubMed
Mignogna 2012
    1. Mignogna J, Cully JA. Depression and anxiety in patients with COPD: a focus on psychological treatments in ambulatory care settings. Current Respiratory Medicine Reviews 2012;8:137‐44.
Mikkelsen 2004
    1. Mikkelsen RL, Middelboe T, Pisinger C, Stage KB. Anxiety and depression in patients with chronic obstructive pulmonary disease (COPD). A review. Nordic Journal of Psychiatry 2004;58(1):65‐70. - PubMed
Miravitlles 2014
    1. Miravitlles M, Cantoni J, Naberan K. Factors associated with a low level of physical activity in patients with chronic obstructive pulmonary disease. Lung 2014;192:259‐65. - PubMed
Moret 2009
    1. Moret C, Isaac M, Briley M. Problems associated with long‐term treatment with selective serotonin reuptake inhibitors. Journal of Psychopharmacology 2009;23(8):967‐74. - PubMed
Mottram 2006
    1. Mottram P, Wilson K, Strobl J. Antidepressants for depressed elderly. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD003491] - DOI - PMC - PubMed
Naylor 2012
    1. Naylor C, Parsonage M, McDaid D, Knapp M, Fossey M, Galea A, The Kings Fund and Centre for Mental Health. Long‐term conditions and mental health. The cost of co‐morbidities. kingsfund.org.uk/publications/long‐term‐conditions‐and‐mental‐health accessed prior to 2 November 2018:1‐32.
Ng 2007
    1. Ng TP, Niti M, Tan WC, Cao Z, Ong KC, Eng P. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Archives of Internal Medicine 2007;167(1):60‐7. - PubMed
Ng 2009
    1. Ng T‐P, Niti M, Fones C, Yap KB, Tan W‐C. Co‐morbid association of depression and COPD: a population‐based study. Respiratory Medicine 2009;103:895‐901. - PubMed
NICE 2009
    1. National Institute for Health and Clinical Excellence. CG91 Depression with a chronic physical health problem: NICE guideline. National Collaborating Centre for Mental Health. London, UK 2009.
NICE 2010
    1. National Institute for Health and Clinical Excellence. CG90 Depression: The treatment and management of depression in adults: NICE guideline (updated edition). National Collaborating Centre for Mental Health. London, UK 2010.
Omachi 2009
    1. Omachi TA, Katz PP, Yelin EH, Gregorich SE, Iribarren C, Blanc PD, et al. Depression and health‐related quality of life in chronic obstructive pulmonary disease. American Journal of Medicine 2009;122(8):778.e9‐15. - PMC - PubMed
Panagioti 2014
    1. Panagioti M, Scott C, Blakemore A, Coventry PA. Overview of the prevalence, impact, and management of depression and anxiety in chronic obstructive pulmonary disease. International Journal of COPD 2014;9:1289‐306. - PMC - PubMed
Papp 1995
    1. Papp L, Weiss J, Greenberg H, Rifkin A, Scharf SM, Gorman JM, et al. Sertraline for chronic obstructive pulmonary disease and comorbid anxiety and mood disorders. American Journal of Psychiatry 1995;152:1531. - PubMed
Patton 1998
    1. Patton GC, Carlin JB, Coffey C, Wolfe R, Hibbert M, Bowes G. Depression, anxiety, and smoking initiation: a prospective study over 3 years. American Journal of Public Health 1998;88(10):1518‐22. - PMC - PubMed
Piek 2010
    1. Piek E, Meer K, Nolen WA. Guideline recommendations for long‐term treatment of depression with antidepressants in primary care: a critical review. European Journal of General Practice 2010;16(2):106‐12. - PubMed
Pignone 2002
    1. Pignone MP, Gaynes BN, Rushton JL, Burchell CM, Orleans CT, Murlow CD, et al. Screening for depression in adults: a summary of the evidence for the U.S. Preventive Services Task Force. Annals of Internal Medicine 2002;136(10):765‐76. - PubMed
Pollok 2016
    1. Pollok J, Agteren J, Carson K, Esterman A, Smith B, Licinio J. Psychological therapies for the treatment of depression in chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2016, Issue 9. [DOI: 10.1002/14651858.CD012347] - DOI - PMC - PubMed
Pooler 2014
    1. Pooler A, Beech R. Examining the relationship between anxiety and depression and exacerbations of COPD which result in hospital admission: a systematic review. International Journal of Chronic Obstructive Pulmonary Disease 2014;9(3):15‐30. - PMC - PubMed
Pumar 2014
    1. Pumar MI, Gray CR, Walsh JR, Yang IA, Rolls TA, Ward DL. Anxiety and depression ‐ important psychological comorbidities of COPD. Journal of Thoracic Disease 2014;6(11):1615‐31. - PMC - PubMed
Rabe 2007
    1. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. American Journal of Respiratory and Critical Care Medicine 2007;176(6):532‐5. - PubMed
Rajkowska 2013
    1. Rajkowska G, Stockmeier CA. Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue. Current Drug Targets 2013;14(11):1225‐36. - PMC - PubMed
Rayner 2010
    1. Rayner L, Price A, Evans A, Valsraj K, Higginson IJ, Hotopf M. Antidepressants for depression in physically ill people. Cochrane Database of Systematic Reviews 2010, Issue 3. [DOI: 10.1002/14651858.CD007503.pub2] - DOI - PubMed
Remick 1988
    1. Remick RA. Anticholinergic side effects of tricyclic antidepressants and their management. Progress in Neuro‐Psychopharmacology & Biological Psychiatry 1988;12(2):225‐31. - PubMed
RevMan 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Rief 2009
    1. Rief W, Nestoriuc Y, Lilienfeld‐Toal A, Dogan I, Schreiber F, Hofmann SG, et al. Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta‐analysis. Drug Safety 2009;32:1041‐56. - PubMed
Ryan 2016
    1. Ryan R, Hill S. How to GRADE the quality of the evidence. Cochrane Consumers and Communication Review Group December 2016.
Sadock 2009
    1. Sadock BJ, Sadock VA, Ruiz P. Kaplan and Sadock's Comprehensive Textbook of Psychiatry. 9th Edition. Philadelphia, London: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2009.
Schatzberg 1992
    1. Schatzberg AF, Rothschild AJ. Serotonin activity in psychotic (delusional) major depression. Journal of Clinical Psychiatry 1992;53:52‐5. - PubMed
Schünemann 2017
    1. Schünemann HJ, Oxman AD, Vist GE, Higgins JP, Deeks JJ, Glasziou P, et al. on behalf of the Cochrane Applicability and Recommendations Methods Group. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook.
Smith 2014
    1. Smith SM, Sonego S, Ketcheson L, Larson JL. A review of the effectiveness of psychological interventions used for anxiety and depression in chronic obstructive pulmonary disease. BMJ Open Respiratory Research 2014;1:1‐10. - PMC - PubMed
Solano 2006
    1. Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. Journal of Pain and Symptom Management 2006;31(1):58‐69. - PubMed
Spitzer 1999
    1. Spitzer RL, Kroenke K, Williams JB, Patient Health Questionnaire Study Group. Validity and utility of a self‐report version of PRIME‐MD: the PHQ Primary Care Study. JAMA 1999;282:1737‐44. - PubMed
Stage 2006
    1. Stage K, Middelboe T, Stage T, Sorensen C. Depression in COPD ‐ management and quality of life considerations. International Journal of COPD 2006;1(3):315‐20. - PMC - PubMed
Sullivan 1998
    1. Sullivan PF, Kendler KS. Typology of common psychiatric syndromes. An empirical study. British Journal of Psychiatry 1998;173:312‐9. - PubMed
Tselebis 2016
    1. Tselebis A, Pachi A, Ilias I, Kosmas E, Bratis D, Moussas G, et al. Strategies to improve anxiety and depression in patients with COPD: a mental health perspective. Neuropsychiatric Disease and Treatment 2016;12:297‐328. - PMC - PubMed
van Manen 2002
    1. Manen JG, Bindels PJ, Dekker FW, IJzermans CJ, Zee JS, Schadé E. Risk of depression in patients with chronic obstructive pulmonary disease and its determinants. Thorax 2002;57(5):412‐6. - PMC - PubMed
Vozoris 2018
    1. Vozoris NT, Wang X, Austin PC, Stephenson AL, O'Donnell DE, Gershon AS, et al. Serotonergic antidepressant use and morbidity and mortality among older adults with COPD. European Respiratory Journal 2018;52:1800475. - PubMed
Ware 1993
    1. Ware JE, Snow KK, Kosinski M, Gandek B. SF‐36 Health Survey: manual and interpretation guide. Boston MA: Health Institute, New England Medical Center, 1993.
WHO 2017
    1. World Health Organization. COPD predicted to be the third leading cause of death in 2030. http://www.who.int/en/news‐room/fact‐sheets/detail/chronic‐obstructive‐p... (accessed prior to 2 November 2018).
Wittchen 2011
    1. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. European Neuropsychopharmacology 2011;21(9):655‐79. - PubMed
Yang 2018
    1. Yang IA, Brown JL, George J, Jenkins S, McDonald CF, McDonald V, et al. The COPD‐X Plan: Australian and New Zealand Guidelines for the Management of Chronic Obstructive Pulmonary Disease 2018. Version 2.53. Lung Foundation Australia, March 2018.
Yin 2017
    1. Yin H, Yin S, Lin Q, Xu Y, Xu H, Liu T. Prevalence of comorbidities in chronic obstructive pulmonary disease patients. Medicine 2017;96(19):e6836. - PMC - PubMed
Yohannes 2005
    1. Yohannes AM, Baldwin RC, Connolly MJ. Predictors of 1‐year mortality in patients discharged from hospital following acute exacerbation of chronic obstructive pulmonary disease. Age and Ageing 2005;34:491‐6. - PubMed
Yohannes 2008
    1. Yohannes AM. Management of anxiety and depression in patients with COPD. Expert Review of Respiratory Medicine 2008;2(3):337‐47. - PubMed
Yohannes 2011
    1. Yohannes A, Connolly M. Do antidepressants work in patients with chronic obstructive pulmonary disease with comorbid depression?. Expert Review of Respiratory Medicine 2011;5(6):727‐9. - PubMed
Yohannes 2014
    1. Yohannes A, Alexopoulos G. Pharmacologic treatment of depression in older patients with COPD: impact on the course of the disease and health outcomes. Drugs & Aging 2014;31(7):483‐92. - PMC - PubMed
Zhang 2011
    1. Zhang MW, Ho RC, Cheung MW, Fu E, Mak A. Prevalence of depressive symptoms in patients with chronic obstructive pulmonary disease: a systematic review, meta‐analysis and meta‐regression. General Hospital Psychiatry Journal 2011;33(3):217‐23. - PubMed

References to other published versions of this review

Naqvi 2016
    1. Naqvi SS, Pollok J, Agteren JEM, Usmani ZA, Carson KV, Smith BJ, et al. Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2016, Issue 9. [DOI: 10.1002/14651858.CD012346] - DOI - PMC - PubMed

Publication types

MeSH terms